Author:
Mazzocco Claire,Genevois Coralie,Li Qin,Doudnikoff Evelyne,Dutheil Nathalie,Leste-Lasserre Thierry,Arotcarena Marie-Laure,Bezard Erwan
Abstract
AbstractAmong the several animal models of α-synucleinopathies, the well-known viral vector-mediated delivery of wild-type or mutated (A53T) α-synuclein requires new tools to increase the lesion in mice and follow up in vivo expression. To this end, we developed a bioluminescent expression reporter of the human A53T-α-synuclein gene using the NanoLuc system into an AAV2/9, embedded or not in a fibroin solution to stabilise its expression in space and time. We first verified the expression of the fused protein in vitro on transfected cells by bioluminescence and Western blotting. Next, two groups of C57Bl6Jr mice were unilaterally injected with the AAV-NanoLuc-human-A53T-α-synuclein above the substantia nigra combined (or not) with fibroin. We first show that the in vivo cerebral bioluminescence signal was more intense in the presence of fibroin. Using immunohistochemistry, we find that the human-A53T-α-synuclein protein is more restricted to the ipsilateral side with an overall greater magnitude of the lesion when fibroin was added. However, we also detected a bioluminescence signal in peripheral organs in both conditions, confirmed by the presence of viral DNA corresponding to the injected AAV in the liver using qPCR.
Funder
French government in the framework of the University of Bordeaux’s IdEx “Investments for the Future”
Labex TRAIL
France Life Imaging
European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program
Publisher
Springer Science and Business Media LLC